Altos Labs Stock

altoslabs.comHealthcare / BioTech & PharmaFounded: 2021Funding to Date: $1.16B

Altos Labs is an American biotechnology research company founded in 2022 and focused on cellular rejuvenation programming to restore cell health and resilience, with the goal of reversing disease to transform medicine. Altos has operations in San Francisco, San Diego, and in Cambridge, UK, with significant collaborations in Japan, with a Board of Directors and advisors including Nobel Laureates and scientific leaders.

Register for Details

For more details on financing and valuation for Altos Labs, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Altos Labs.

Register Today


Management Team

Hans Bishop
Co-Founder & President
Ann Lee-Karlon Ph.D
Chief Operating Officer
Hal Barron MD
Chief Executive Officer
Richard Klausner MD
Co-Founder & Chief Scientist

Other companies like Altos Labs in the BioTech & Pharma sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation

News Highlights

For This Venture Capitalist, Research on Aging Is Personal; ‘Bob Has a Big Fear of Death’
The investment firm Robert Nelsen co-founded in 1986, Arch Venture Partners, has racked up billions in profits from early stakes in companies developing methods to detect and treat cancer and other diseases.
Altos Labs launches with the goal to transform medicine through cellular rejuvenation programming
Altos Labs™ (Altos™) launched today as a new biotechnology company dedicated to unraveling the deep biology of cellular rejuvenation programming. Altos' mission is to restore cell health and resilience to reverse disease, injury, and the disabilities that can occur throughout life. The company launches with a community of leading scientists, clinicians, and leaders from both academia and industry working together towards this common mission.
Updated on: Oct 3, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.